• Basecamp Research lance les premiers modèles d’IA pour l’insertion de gènes programmables 
• Développé en collaboration avec NVIDIA à travers l’apprentissage des plus grands modèles d’IA évolutionnaires sur un nouvel ensemble de données recueillies à l’échelle mondiale et accélérées par NVIDIA BioNeMo.
• Le même modèle polyvalent a également permis de concevoir de nouvelles molécules peptidiques antimicrobiennes avec un taux de réussite de 97 % confirmé en laboratoire, y compris des candidats qui se sont révélés très puissants contre les « superbactéries » multirésistantes.
• Basecamp Research compte également NVentures parmi ses investisseurs avant la série C, à la suite d’une collaboration technique approfondie sur les modèles EDEN.

LONDRES et CAMBRIDGE, Massachusetts, — Basecamp Research, un laboratoire d’IA d’avant-garde qui utilise l’évolution pour concevoir de nouveaux médicaments, a annoncé aujourd’hui les premiers modèles d’IA capables d’insérer des gènes programmables, offrant une nouvelle façon de remplacer les gènes défectueux et de reprogrammer les cellules à des fins thérapeutiques. Suite à un apprentissage en collaboration avec NVIDIA, ces modèles sont à l’origine du développement d’une nouvelle génération de traitements contre le cancer et les maladies héréditaires. Parallèlement, Basecamp Research a obtenu un investissement de NVentures (la branche de capital-risque de NVIDIA) dans le cadre de son cycle de pré-série C, après plusieurs années d’étroite collaboration technique, ce qui aidera la société à accélérer ses efforts de recherche et de développement.

« Nous pensons que nous sommes au début d’une expansion majeure de ce qui est possible pour les patients atteints de cancer et de maladies génétiques », a déclaré John Finn, directeur scientifique de Basecamp Research. « En utilisant l’IA pour concevoir l’enzyme thérapeutique, nous espérons accélérer le développement de traitements de milliers de maladies incurables, pour potentiellement transformer des millions de vies. »

Insertion de gènes programmable

L’insertion de gènes programmable – consistant à placer d’importantes séquences d’ADN thérapeutiques à des endroits précis du génome humain – est un objectif central de la médecine génétique depuis des décennies. Les approches actuelles basées sur CRISPR ne peuvent effectuer que de petites modifications et doivent endommager l’ADN au cours du processus, ce qui limite les possibilités d’utilisation. Basecamp Research est le premier à démontrer que l’IA peut concevoir des enzymes capables d’insérer des gènes à grande échelle dans des sites définis du génome humain, ouvrant ainsi une voie longtemps recherchée vers des traitements programmables.

La plateforme AI-Programmable Gene Insertion (aiPGI^™) de Basecamp Research est activée par EDEN, une nouvelle gamme de modèles d’IA évolutifs développés avec NVIDIA et ayant suivi un apprentissage sur BaseData^™, l’ensemble de données génomiques propriétaire de la société, le plus grand de son genre. Les modèles apprennent le langage de l’ADN et les modèles d’évolution, permettant ainsi aux algorithmes de concevoir de nouvelles thérapies programmables pour le cancer et les maladies génétiques.

Dans les résultats de laboratoire publiés aujourd’hui dans un article co-écrit par NVIDIA, Microsoft et d’éminents universitaires, [link], les modèles EDEN ont conçu plusieurs protéines d’insertion actives pour 100 % des sites cibles testés pertinents pour la maladie dans le génome humain, en ne nécessitant que le site cible génomique comme invite et en marquant une avancée considérable dans la capacité des modèles d’intelligence artificielle.

Basecamp Research a déjà démontré l’insertion dans plus de 10 000 endroits du génome humain liés à des maladies, y compris l’intégration thérapeutique de l’ADN anticancéreux dans les cellules T humaines primaires dans de nouveaux sites d’accueil. Cela a permis de produire des cellules CAR-T qui tuent très efficacement les cellules cancéreuses, avec une élimination de plus de 90 % des cellules tumorales lors d’essais en laboratoire.

Des molécules conçues par l’IA pour lutter contre les « superbactéries »

Sur un autre front majeur de la conception thérapeutique, à savoir la crise mondiale de la résistance aux médicaments, le même modèle a prouvé sa polyvalence en concevant une bibliothèque ciblée de nouveaux peptides antimicrobiens (AMP) – de petites protéines ayant le potentiel de tuer les bactéries nocives – avec 97 % des candidats démontrant une activité confirmée dans les tests de laboratoire. Dans le cadre d’une collaboration avec des scientifiques de l’université de Pennsylvanie dirigés par le professeur César de la Fuente, les AMP les plus performants ont fait preuve d’une grande efficacité contre les agents pathogènes multirésistants prioritaires, offrant ainsi un nouvel outil puissant dans la lutte contre les « superbactéries » dangereuses.

Une avancée décisive basée sur des données uniques et des modèles d’IA d’avant-garde

Les modèles EDEN qui activent aiPGI^™ ont suivi un apprentissage sur plus de 10 000 milliards de jetons d’ADN évolutif provenant de plus d’un million d’espèces nouvellement découvertes. Ces données ont été recueillies pendant cinq ans dans plus de 150 lieux répartis dans 28 pays et sur cinq continents, dans le cadre d’une nouvelle stratégie de collecte de données mise en place par l’entreprise, publiée en juin 2025.

Le plus grand modèle EDEN a suivi un apprentissage sur 1,95 x 10²⁴ FLOPS de calcul sur un cluster de 1 008 GPU NVIDIA Hopper et accéléré avec des bibliothèques de NVIDIA BioNeMo, ce qui le rend comparable à l’échelle des modèles de la classe GPT-4 et le place parmi les modèles biologiques les plus intensifs en calcul jamais rapportés.

Actifs thérapeutiques en développement

Ces capacités sont à la base de la nouvelle gamme de traitements cellulaires et géniques de Basecamp Research, ouvrant la voie à des traitements plus précis, plus prévisibles et plus personnalisés que ceux disponibles aujourd’hui. L’objectif de l’entreprise est de développer des thérapies potentiellement curatives pour tout un éventail de cancers et de maladies génétiques, grâce aux améliorations continues de BaseData^™, les modèles EDEN et aiPGI^™.

À propos de Basecamp Research
Basecamp Research se consacre à la résolution de défis majeurs dans le domaine des sciences de la vie en explorant au-delà de la biologie connue^™. L’entreprise construit des modèles d’IA d’avant-garde en utilisant BaseData, le plus grand ensemble de données biologiques représentatives au niveau mondial et provenant de sources éthiques. Basecamp Research recueille et conserve ses propres données biologiques grâce à des partenariats avec plus de 152 organisations dans 28 pays, ce qui permet à son IA d’accéder à une diversité génétique qui n’existe pas pour les modèles formés à partir de bases de données publiques. Cela permet à Basecamp Research de concevoir de nouvelles séquences de protéines et de nouveaux systèmes biologiques susceptibles d’accélérer la recherche et le développement thérapeutiques.

Basecamp Research travaille en partenariat avec des entreprises biopharmaceutiques et des institutions académiques dans le monde entier, et son travail a été récompensé par des distinctions telles que sa présence dans le palmarès des 10 entreprise les plus innovantes de Fast Company et dans la liste Sifted AI100, soutenue par le FT, des meilleures startups européennes dans le domaine de l’intelligence artificielle. Pour en savoir plus, consultez le site basecamp-research.com.

BaseData^™, Beyond Known Biology^™, EDEN-GLM^™ et aiPGI^™ sont des marques et des technologies de Basecamp Research.

• Mit diesem Durchbruch wird eine seit langem bestehende Herausforderung in der Genmedizin in Angriff genommen, um eine neue Generation von heilenden Zell- und Gentherapien zu entwickeln.
• Entwickelt in Zusammenarbeit mit NVIDIA durch das Training der größten evolutionären KI-Modelle auf einem neuen, weltweit erhobenen Datensatz, beschleunigt durch NVIDIA BioNeMo.
• Dasselbe vielseitige Modell half auch bei der Entwicklung neuartiger antimikrobieller Peptidmoleküle mit einer im Labor bestätigten Erfolgsquote von 97 %, darunter Kandidaten, die sich als hochwirksam gegen multiresistente „Superbugs” erwiesen.
• Basecamp Research gewinnt außerdem NVentures als Investor vor der Series C-Finanzierungsrunde nach intensiver technischer Zusammenarbeit bei EDEN-Modellen.

LONDON und CAMBRIDGE, Massachusetts, — Basecamp Research, ein Pionierlabor für KI, das sich die Evolution zunutze macht, um neue Medikamente zu entwickeln, gab heute die ersten KI-Modelle bekannt, die in der Lage sind, programmierbare Gene einzufügen, und damit eine neue Möglichkeit bieten, fehlerhafte Gene zu ersetzen und Zellen für therapeutische Zwecke umzuprogrammieren. Diese in Zusammenarbeit mit NVIDIA ausgebildeten Modelle treiben die Entwicklung einer neuen Generation von Behandlungen für Krebs und Erbkrankheiten voran. Gleichzeitig sicherte sich Basecamp Research nach mehrjähriger enger technischer Zusammenarbeit eine Investition von NVentures (NVIDIAs Risikokapitalarm) in seiner Pre-Series-C-Runde, die dem Unternehmen helfen wird, seine Forschungs- und Entwicklungsbemühungen zu beschleunigen.

„Wir glauben, dass wir am Anfang einer großen Erweiterung der Möglichkeiten für Patienten mit Krebs und genetischen Erkrankungen stehen”, sagte John Finn, Chief Scientific Officer bei Basecamp Research. „Durch den Einsatz von KI bei der Entwicklung des therapeutischen Enzyms hoffen wir, die Entwicklung von Heilmitteln für Tausende von unbehandelbaren Krankheiten zu beschleunigen und damit möglicherweise das Leben von Millionen von Menschen zu verändern.”

Programmierbare Gen-Insertion

Die programmierbare Gen-Insertion – die Platzierung großer therapeutischer DNA-Sequenzen an präzisen Stellen im menschlichen Genom – ist seit Jahrzehnten ein zentrales Ziel der Genmedizin. Bestehende CRISPR-basierte Ansätze können nur kleine Änderungen vornehmen und müssen dazu die DNA beschädigen, was ihre Einsatzmöglichkeiten einschränkt. Basecamp Research hat als erstes Unternehmen gezeigt, dass KI Enzyme entwerfen kann, die in der Lage sind, große Mengen an Genen an bestimmten Stellen in das menschliche Genom einzufügen, und damit einen lange gesuchten Weg zu programmierbaren Therapien eröffnet.

Die Plattform AI-Programmable Gene Insertion (aiPGI^™) von Basecamp Research wird von EDEN angetrieben, einer neuen Familie evolutionärer KI-Modelle, die mit NVIDIA entwickelt und auf BaseData^™ trainiert wurden, dem proprietären und seiner Art nach größten Genomik-Datensatz des Unternehmens. Die Modelle lernen die Sprache der DNA und die Muster der Evolution, so dass die Algorithmen neue, programmierbare Therapien für Krebs und genetische Krankheiten entwickeln können.

In den Laborergebnissen, die heute in einer von NVIDIA, Microsoft und führenden Wissenschaftlern gemeinsam verfassten Publikation [Link] veröffentlicht wurden, haben die EDEN-Modelle mehrere aktive Insertionsproteine für 100 % der getesteten krankheitsrelevanten Zielstellen im menschlichen Genom entworfen, wobei nur die genomische Zielstelle als Eingabeaufforderung erforderlich war. Dies markiert einen signifikanten Fortschritt in der Leistungsfähigkeit von KI-Modellen.

Basecamp Research hat bereits die Insertion an über 10.000 krankheitsrelevanten Stellen im menschlichen Genom nachgewiesen, einschließlich der therapeutisch relevanten Integration krebsbekämpfender DNA in primäre menschliche T-Zellen an neuartigen Safe-Harbour-Stellen. Daraus entstanden CAR-T-Zellen, die Krebszellen stark abtöten und in Labortests über 90 % der Tumorzellen vernichten.

KI-entwickelte Moleküle zur Bekämpfung von „Superbugs”

Bei einer anderen wichtigen Pionieraufgabe im Bereich des therapeutischen Designs, die auf die weltweite Krise der Arzneimittelresistenz abzielt, bewies dasselbe Modell seine Vielseitigkeit, indem es eine gezielte Bibliothek neuartiger antimikrobieller Peptide (AMPs) – kleine Proteine mit dem Potenzial, schädliche Bakterien abzutöten – entwarf, wobei 97 % der Kandidaten in Labortests eine bestätigte Aktivität aufwiesen. In Zusammenarbeit mit Wissenschaftlern der University of Pennsylvania unter der Leitung von Prof. César de la Fuente zeigten die am besten abschneidenden AMPs eine hohe Wirksamkeit gegen kritische, multiresistente Krankheitserreger und bieten damit ein leistungsstarkes neues Instrument im Kampf gegen gefährliche „Superbugs”.

Durchbruch dank einzigartiger Daten und bahnbrechender KI-Modelle

Die EDEN-Modelle, die aiPGI^™ antreiben, wurden auf über 10 Billionen Token evolutionärer DNA von mehr als einer Million neu entdeckter Arten trainiert. Diese Daten wurden über einen Zeitraum von fünf Jahren an über 150 Standorten in 28 Ländern und auf fünf Kontinenten im Rahmen einer neuartigen, vom Unternehmen entwickelten Datenerhebungsstrategie gesammelt und im Juni 2025 veröffentlicht.

Das größte EDEN-Modell wurde mit einer Rechenleistung von 1,95 x 10²⁴ FLOPS auf einem Cluster von 1.008 NVIDIA Hopper GPUs trainiert und mit Bibliotheken von NVIDIA BioNeMo beschleunigt. Damit ist es von der Größenordnung her mit Modellen der Klasse GPT-4 vergleichbar und zählt zu den rechenintensivsten biologischen Modellen, die jemals gemeldet wurden.

Therapeutische Wirkstoffe in der Entwicklung

Diese Fähigkeiten untermauern die entstehende Pipeline von Zell- und Gentherapien von Basecamp Research und ebnen den Weg für Behandlungen, die präziser, besser vorhersagbar und individueller sind als die heute verfügbaren. Das Ziel des Unternehmens ist es, potenziell heilende Therapien für eine Reihe von Krebs- und genetischen Erkrankungen zu entwickeln, gestützt auf kontinuierliche Verbesserungen von BaseData^™, den EDEN-Modellen und aiPGI^™.

Informationen zu Basecamp Research
Basecamp Research widmet sich der Lösung zentraler Herausforderungen in den Biowissenschaften durch die Erforschung von Beyond Known Biology^™. Das Unternehmen erstellt bahnbrechende KI-Modelle auf der Grundlage von BaseData, dem weltweit größten ethisch fundierten und global repräsentativen biologischen Datensatz. Basecamp Research sammelt und kuratiert seine eigenen biologischen Daten durch Partnerschaften mit mehr als 152 Organisationen in 28 Ländern und verschafft seiner KI damit Zugang zu einer genetischen Vielfalt, die für Modelle, die auf öffentlichen Datenbankquellen trainiert werden, nicht existiert. Dadurch kann Basecamp Research neue Proteinsequenzen und biologische Systeme entwerfen, die die therapeutische Forschung und Entwicklung beschleunigen können.

Basecamp Research arbeitet mit biopharmazeutischen Unternehmen und akademischen Einrichtungen auf der ganzen Welt zusammen. Die Arbeit von Basecamp Research wurde mit Auszeichnungen gewürdigt, darunter Fast Company’s Top 10 Most Innovative Companies in Biotech und die von FT unterstützte Sifted AI100-Liste der führenden KI-Startups in Europa. Weitere Informationen finden Sie unter basecamp-research.com.

BaseData^™, Beyond Known Biology^™, EDEN-GLM^™ und aiPGI^™ sind Markennamen und Technologien von Basecamp Research.

• The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies.
• Developed in collaboration with NVIDIA by training the largest evolutionary AI models on a new, globally collected dataset, accelerated by NVIDIA BioNeMo.
• The same versatile model also helped design novel antimicrobial peptide molecules with a 97% lab-confirmed success rate, including candidates that appeared highly potent against multidrug-resistant “superbugs.”
• Basecamp Research also adds NVentures as an investor ahead of Series C round following deep technical collaboration on EDEN models.

LONDON and CAMBRIDGE, Mass., Jan. 12, 2026 — Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, today announced the first AI models capable of programmable gene insertion, offering a new way to replace faulty genes and reprogram cells for therapeutic use. Trained in collaboration with NVIDIA, these models are driving the development of a new generation of treatments for cancer and inherited diseases. In parallel, Basecamp Research secured an investment from NVentures (NVIDIA’s venture capital arm) in its pre-Series C round following years of close technical collaboration, which will help the company to accelerate its research and development efforts.

“We believe we are at the start of a major expansion of what’s possible for patients with cancer and genetic disease,” said John Finn, Chief Scientific Officer at Basecamp Research. “By using AI to design the therapeutic enzyme, we hope to accelerate the development of cures for thousands of untreatable diseases, potentially transforming millions of lives.”

Programmable Gene Insertion

Programmable gene insertion – placing large therapeutic DNA sequences at precise locations in the human genome – has been a central goal in genetic medicine for decades. Existing CRISPR-based approaches can only make small edits and must damage DNA to do so, limiting where and how they can be used. Basecamp Research is the first to demonstrate that AI can design enzymes capable of performing large gene insertion at defined sites in the human genome, opening a long-sought path toward programmable therapies.

Basecamp Research’s AI-Programmable Gene Insertion (aiPGI^™) platform is powered by EDEN, a new family of evolutionary AI models developed with NVIDIA, trained on BaseData^™, the company’s proprietary genomics dataset – the largest of its kind. The models learn the language of DNA and patterns of evolution, allowing the algorithms to design new, programmable therapies for cancer and genetic disease.

In lab results published today in a paper co-authored by NVIDIA, Microsoft and leading academics, [link], the EDEN models designed multiple active insertion proteins for 100% of tested disease-relevant target sites in the human genome, requiring only the genomic target site as a prompt and marking a significant step forward in AI model capability.

Basecamp Research has already demonstrated insertion at over 10,000 disease-related locations in the human genome, including therapeutically relevant integration of cancer-fighting DNA into primary human T cells at novel safe-harbour sites. This produced CAR-T cells that show strong killing of cancer cells, showing over 90% tumour-cell clearance in laboratory assays.

AI-Designed Molecules To Fight “Superbugs”

In another key frontier therapeutic design task targeting the global drug-resistance crisis, the same model proved its versatility by designing a focused library of novel antimicrobial peptides (AMPs) – small proteins with the potential to kill harmful bacteria – with 97% of candidates demonstrating confirmed activity in laboratory tests. In a collaboration with University of Pennsylvania scientists led by Prof. César de la Fuente, the top-performing AMPs showed high potency against critical-priority, multidrug-resistant pathogens, offering a powerful new tool in the fight against dangerous “superbugs.”

Breakthrough powered by unique data & frontier AI models

The EDEN models that power aiPGI^™ were trained on over 10 trillion tokens of evolutionary DNA from more than one million newly-discovered species. This data was collected over five years from over 150 locations across 28 countries and five continents as part of a novel data collection strategy pioneered by the company, published in June 2025.

The largest EDEN model was trained on 1.95×10²⁴ FLOPS of compute on a cluster of 1,008 NVIDIA Hopper GPUs and accelerated with libraries from NVIDIA BioNeMo, making it comparable in scale to GPT-4 class models and placing it among the most computationally intensive biological models ever reported.

Therapeutic assets in development

These capabilities underpin Basecamp Research’s emerging pipeline of cell and gene therapies, opening the path to treatments that are more precise, predictable and personalised than those available today. The company’s goal is to develop potentially curative therapies across a range of cancer and genetic disease indications, powered by continued improvements to BaseData^™, the EDEN models and aiPGI^™.

About Basecamp Research
Basecamp Research is dedicated to solving major challenges in the life sciences by exploring Beyond Known Biology^™. The company builds frontier AI models using BaseData, the world’s largest ethically-sourced and globally representative biological dataset. Basecamp Research collects and curates its own biological data through partnerships with more than 152 organizations in 28 countries, giving its AI access to genetic diversity that doesn’t exist for models trained on public database sources. This allows Basecamp Research to design novel protein sequences and biological systems that can accelerate therapeutic research and development.

Basecamp Research partners with biopharma companies and academic institutions worldwide, and its work has been recognized with honors including Fast Company’s Top 10 Most Innovative Companies in Biotech and the FT-backed Sifted AI100 list of Europe’s leading AI startups. Learn more at basecamp-research.com.

BaseData^™, Beyond Known Biology^™, EDEN-GLM^™ and aiPGI^™ are brand names and technologies of Basecamp Research.

SOURCE Basecamp Research

Total funding reaches €13 million as company prepares for upcoming product launches

LINKÖPING, Sweden, Jan. 12, 2026 — Polar Light Technologies AB (“Polar Light”), a Swedish semiconductor innovator specializing in next-generation MicroLED technology, today announced the successful closing of a €5 Million+ funding round.

The additional funds will advance the rollout of Polar Light’s initial products, all based on its pyramidal MicroLED platform. The round was led by J2L Holding AB, with participation from STOAF, Almi Invest and Butterfly Ventures.

MicroLED is widely regarded as a revolutionary display technology due to its unparalleled brightness and low power consumption, making it possible to create whole new categories of display types for a wide variety of novel use cases.

“Last May, we unveiled our first MicroLED display prototype. Today’s funding announcement gives us the required runway to bring our first products to market,” said Oskar Fajerson, CEO of Polar Light Technologies. “MicroLED represents the future beyond LCD and OLED, with vast market potential. Our initial focus will be on small purpose-built HUD displays, followed swiftly by applications in smart glasses and wearables.”

“Polar Light Technologies is the global leader in developing the next-generation MicroLED technology that will power tomorrow’s display applications,” said Johan Lindh, CEO of J2L Holding AB. “As the market begins to scale, Polar Light is well positioned to lead the way with innovations that make MicroLED displays easier to produce and far more accessible to integrate.”

In 2025, Polar Light demonstrated its first public prototype at Display Week and showed an updated display at MicroLED Connect in September. To learn more, visit Technology – Polar Light Technologies. 

About Polar Light Technologies
Headquartered in Linköping, Sweden, Polar Light Technologies is the leading developer of next-generation MicroLED technologies. Polar Light’s unique architecture uses pyramidal structures grown without etching. This enables full RGB on a single epi-wafer and is a foundation for sub-MicroLED innovations, while delivering exceptional brightness and energy efficiency for advanced display applications. For more information, visit Polar Light Technologies.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/polar-light-technologies-ab/r/polar-light-technologies-secures–5-million–funding-round-to-accelerate-microled-commercialization,c4290583

The following files are available for download:

Startup’s TSP1 State Space Accelerator Chip Delivers On-Device Voice AI for AR, Robotics, Wearables, Medical Devices, and Automotive Applications

WATERLOO, ON, Jan. 12, 2026 – Applied Brain Research (ABR), the leader in low latency real-time on-device voice AI solutions, announced today the successful closure of its oversubscribed seed funding round. The investment round was led by Two Small Fish Ventures (TSF), with Eva Lau joining the ABR board. The investment will fuel continued development and commercialization of ABR’s breakthrough TSP1 state space accelerator chip and software models for edge AI inference applications. ABR is a unique full-stack edge AI company, delivering patented state space models and purpose-built silicon to enable unmatched real-time, low-power voice AI fully on-device.

The oversubscribed seed round closed following the successful release of ABR’s TSP1 chip, the company’s first-generation state space accelerator purpose-built for real-time time series processing at the edge. The TSP1 enables on-device automatic speech recognition (ASR), text-to-speech (TTS), and advanced digital signal processing applications – capabilities that have traditionally required cloud connectivity or significantly more powerful hardware.

“Voice is becoming the default interface for the next wave of edge devices but using cloud voice AI solutions is a terrible experience, plagued by delays, reliability and privacy concerns while also being very expensive. And most edge devices are constrained by their battery life and computational resources limiting on-device capabilities,” said Kevin Conley, CEO of Applied Brain Research. “We’re elevating the experience of super responsive on-device voice interaction with low power solutions that also significantly reduce device operating costs.”

As was seen the past week at CES, ABR’s technology addresses critical pain points across multiple product segments where reliable, low-latency voice processing is essential but cloud connectivity is impractical, unreliable, expensive, and poses privacy concerns. There was clear resonance for ABR solutions in several categories:

• Augmented Reality Glasses: Elevating on-device voice control and responsive agent integration
• Robotics: Enabling zero delay cloud agent integrations and eliminating crippling operating costs
• Wearables: Unlocking a new level of AI voice control possibilities
• Medical Devices: More powerful biosensor on-device inference that protects sensitive data
• Automotive: Consistent in-vehicle voice experiences regardless of network connectivity

The TSP1’s architecture, optimized for state space model inference, represents a fundamental advance in efficient AI computation, enabling complex neural network inference at a fraction of the power budget required by conventional approaches. Full vocabulary speech-to-text and text-to-speech are now possible at under 30mW of power consumption, 10–100 times less than other available alternatives.

“The embedded AI market is at an inflection point,” said Eva Lau, General Partner at Two Small Fish Ventures. “Applied Brain Research has demonstrated that sophisticated voice AI doesn’t require the cloud. Their technology unlocks entirely new product categories and use cases that weren’t previously viable.”

ABR is currently engaging with partners across the AR, robotics, wearables, medical device, and automotive sectors. The company offers both the TSP1 chip and optimized software models tailored to specific application requirements.

About Applied Brain Research

Applied Brain Research Inc. (ABR) is an AI solution company focused on dramatically reducing the cost, latency and power consumption of edge AI applications. The company’s patented State Space Model  (SSM) technology improves the user experience and economics of everything from AR glasses to sophisticated robots. ABR’s SSM technology solves the computational resource constraints that limit edge AI solutions by enabling deployment of powerful real-time AI, alleviating the constraints, latency and costs of cloud-based AI. ABR licenses SSM software for existing hardware applications and sells its accelerator ASIC, the TSP1 for industry leading lowest power levels.

Additional details about ABR’s SSMs and the TSP1 can be found at https://www.eetimes.com/applied-brain-research-demos-first-silicon-for-state-space-models/

Corporate information can be found at www.appliedbrainresearch.com.

SOURCE Applied Brain Research Inc.

• Novel use of Causal AI revives long-stalled development pathways across complex generics and next-generation medicines for chronic disease
• Allos bends the cost-risk curve of drug development and formulation for complex generics, making specialty medicines easier to take, optimized for long-term use, and economically viable
• Allos’ approach gives drug developers, innovators, and generic manufacturers a reason to reinvest in complex drugs that have historically failed to progress

OXFORD, United Kingdom, Jan. 12, 2026 — Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry’s first “glass-box” Causal AI platform, accelerating the end-to-end reformulation of complex generic drugs. The round also included participation from Habico Invest, the family office of Danish pharmaceutical group Orifarm, and the University of California accelerator Berkeley SKYDECK. The funding will support expansion across formulation development and data science as the company focuses on hard-to-genericize small-molecule medicines.

Millions of people with chronic, complex conditions take specialty drugs as part of daily life. These medicines often do what they are meant to do clinically, but how they are formulated and delivered can make them difficult to tolerate, adhere to, or sustain over time. When formulation and delivery create friction for patients, improving an approved drug often requires rebuilding the development and clinical pathway.

Despite clear opportunities in drug life-cycle management to improve delivery, tolerability, and long-term outcomes, most drugs are rarely revisited once they reach the market, including approved generics and early new chemical entities (NCEs). Patients remain on suboptimal formulations for years, while manufacturers hesitate to invest in changes that carry high development cost, clinical risk, and regulatory uncertainty. This gap persists even as the global specialty generics market rapidly grows, rising from $77B USD in 2023 to a projected $275B USD by 2032, underscoring the scale of unmet clinical and commercial opportunity.

Allos applies Causal AI to reformulate complex small-molecule drugs by modeling how formulation, dosing, delivery, and patient biology interact to drive clinical outcomes. By modeling how formulation, dosing, and delivery choices influence outcomes across stratified patient populations, Allos identifies reformulation paths that produce more predictable clinical benefit.

This approach enables clinical studies that are smaller, faster, and more interpretable for partners while reducing inter-patient variability. Using real world evidence to account for patient and disease heterogeneity upfront, Allos reduces development uncertainty, shortens timelines, and lowers the burden associated with reformulating complex drugs, creating a more predictable path to approval and licensing.

“For decades, the pharmaceutical system has treated approval as the finish line, even though for patients it marks the start of a much longer journey,” said Aditya Iyer, PhD, CEO and co-founder of Allos AI. “What’s been missing is a practical way to keep improving medicines after they reach the market, without relying on workarounds or intuition. With Causal AI, we’re building a development platform that allows improvement to be intentional, evidence-driven, and repeatable. Over time, that has the potential to fundamentally change how complex drugs are developed, maintained, and experienced.”

“Most AI efforts in drug development focus on discovering new molecules, but that’s not where the near-term opportunity lies,” said Joel Schoppig, Health Tech Investment Principal, Oxford Science Enterprises. “AI has been pointed at problems that take decades to commercialize, while the biggest barriers in patient care stem from how existing drugs are formulated and delivered. Allos applies Causal AI where it can have immediate impact: improving medicines that already work but remain limited by tolerability, bioavailability, or delivery. By turning reformulation into an evidence-driven engineering discipline, Allos has the potential to reshape how complex generics and high-risk NCE programs advance.”

About Allos AI
Allos AI uses Causal AI to transform existing complex drugs into more bioavailable, safer, and easier-to-take medicines. Founded by a team that brings together an Oxford-trained quantum physicist, applied AI researchers, and industry veterans in complex generics, Allos combines deep scientific expertise with real-world drug development experience. The AI-native company reformulates small-molecule drugs and designs clinical studies grounded in real world evidence from health records that bring molecules to market faster and with greater confidence. Allos collaborates with pharmaceutical companies to modernize legacy assets, unlock stalled programs, and expand access to complex generics. Learn more at allos.ai.

Media Contact:
[email protected]

SOURCE Allos

PORTLAND, Ore., Jan. 12, 2026 — Elevate Capital announced continued momentum across its Oregon investment strategy, with $1.6 million deployed into five Oregon-based startups through a state-backed venture capital initiative.

The investments reflect Elevate’s ongoing commitment to backing high-potential founders, expanding access to early-stage capital, and supporting long-term economic growth across Oregon. The capital was deployed through Oregon’s Venture Direct program, supported by the federal State Small Business Credit Initiative (SSBCI).

Since receiving the fund’s first tranche of capital, Elevate has completed investments in:

• Overwatch Imaging – $500,000
• CleanHaus – $250,000
• PortalSphere – $250,000
• StrateSea – $350,000
• Osheru – $250,000

“From day one, Elevate understood what we’re building and the challenges founders face at this stage. Their hands-on approach and long-term perspective made a meaningful difference for CleanHaus,” said Nat Parker, founder of CleanHaus.

All investments were selected through Elevate’s rigorous diligence process and supported by matching private capital at the time of investment, ensuring strong market validation and long-term scalability.

“We launched this program with the shared goal of expanding access to early-stage capital for Oregon entrepreneurs,” said Nitin Rai, Elevate Capital Founder. “These first investments demonstrate the quality of emerging companies in Oregon and the catalytic power of pairing public capital with private investment.”

Elevate was selected by Business Oregon to manage the venture capital component of SSBCI based on its strong performance managing the state’s Innovation Gap Funds I & II, deep roots in Oregon’s entrepreneurial ecosystem, and commitment to supporting diverse and underserved founders.

“Deploying capital into early-stage companies is already strengthening Oregon’s innovation ecosystem,” said Ben Nahir, Venture Principal at Elevate Capital.  “We’re excited to see Elevate supporting new founders with the resources and guidance needed to scale.”

About the Program
The SSBCI Venture Direct Program provides federally funded, state-managed capital designed to stimulate economic growth. Companies must be headquartered in Oregon, have a majority of employees in Oregon, or maintain a principal Oregon business location.

How to Apply
Oregon-based founders seeking early-stage funding can apply through Elevate’s website at elevate.vc.

About Elevate Capital
Founded in 2016, Elevate Capital is the nation’s first institutional venture capital fund primarily targeting investments in underestimated founders and those with limited regional access to capital and opportunities. Through the SSBCI and Innovation Gap Funds, Elevate also supports high-risk research-driven innovation in Oregon by investing at the earliest stages in startups from healthcare, life sciences, cleantech, sustainability, and other target-traded sector industries.

Visit elevate.vc or follow Elevate Capital on X, Facebook and LinkedIn.

SOURCE Elevate Capital

Saama Capital Founder Ash Lilani and Former Procter & Gamble Chief Innovation Officer Jerry Porter Join DaVinci Commerce Board of Directors

SAN MATEO, Calif., Jan. 12, 2026 — DaVinci Commerce, formerly named Jivox, today announced that it has raised a strategic round of financing to invest in the growth of its AI-native DaVinci Commerce platform designed to help large global brands and commerce media networks scale consumer engagement and acquisition through agentic commerce marketing. This financing follows accelerating adoption of DaVinci Commerce, as large consumer goods and retail enterprises seek to deploy agentic AI to scale commerce marketing. DaVinci Commerce meets this demand with an agentic commerce marketing platform that brings together AI-powered commerce content optimization and agentic commerce media activation—automating campaign activation in minutes across commerce media networks through an architecture enforced by enterprise guardrails. DaVinci Commerce is recognized as a Top 50 innovation at the 2026 National Retail Federation (NRF) Innovators Showcase, highlighting its leadership in bringing agentic AI to commerce marketing.

Commerce media continues to be one of the fastest-growing segments in digital advertising, based on eMarketer’s May 2025 forecast projecting U.S. commerce media ad spend at a 15.3% CAGR from 2025–2029. While eMarketer’s forecast reflects the scale and pace of category growth, market adoption is widely understood to be shaped by broader industry dynamics, including the increasing convergence of commerce media, programmatic buying, and closed-loop measurement. At the same time, enterprises are rapidly adopting AI—and increasingly, agentic AI—to automate complex, multi-step workflows that previously required significant human coordination. DaVinci Commerce was designed from the ground up to operate at this intersection.

“Commerce media growth is no longer limited by media spend but constrained by the ability to handle speedy launches, multi-retailer complexity, and compliance,” said Diaz Nesamoney, Founder & CEO of DaVinci Commerce. “We built the DaVinci Commerce platform from the ground up to be AI-native, enabling brands to lower the cost and complexity of creating and running commerce campaigns across multiple retail media networks while improving performance through personalized commerce ads—all with enterprise-grade guardrails. As demand for agentic commerce marketing continues to accelerate, we raised this round of financing to further invest in product innovation and expand our go-to-market efforts.”

This round of investment in DaVinci Commerce is backed by a distinguished group of technology and enterprise leaders, including:

• Saama Capital, a Silicon Valley venture capital firm focusing on AI and Commerce technologies as a key investment area.
• Amit Singhal, formerly Senior Vice President and Google Fellow who led Google’s core search team for over 15 years, overseeing the development and quality of the company’s search algorithms and shaping the evolution of Google Search.
• Sohaib Abbasi, a technology executive who served as CEO and Chairman of Informatica—where he led substantial growth. Sohaib was also part of the early founding team and held several executive leadership roles at Oracle. He has since served on multiple technology company boards and in senior advisory roles.
• Cosmos Nicolau, a senior engineering leader at Akamai, Fabric7, Google, GRAIL Bio and Neeva. As an early VP at Google he led teams that worked on search and cloud infrastructure, as well as consumer products including Shopping, News, Video, and Image Search.

DaVinci Commerce also announced that Ash Lilani, Founder and Managing Partner of Saama Capital, and Jerry Porter, who was recently Chief Research and Innovation Officer at Procter & Gamble Fabric & Homecare, have joined the board of directors. DaVinci Commerce’s board also includes Greg Archibald, VP of Global Ad Sales at PayPal, and Robert Chatwani, President of DocuSign and was previously CMO of Atlassian and CMO of eBay North America.

“I am very excited to be teaming up with Diaz who is a seasoned serial entrepreneur with several prior successful ventures. AI is transforming the world of commerce marketing and DaVinci Commerce hit the market at exactly the right time when all enterprises are wanting to leverage AI to adapt to the rapidly changing consumer landscape of LLM-driven conversational commerce,” said Ash Lilani of Saama Capital.

“CPG brands globally are seeing tremendous opportunity to leverage first-party consumer data and conversational signals to engage with and acquire customers in a personalized way,” said Jerry Porter.  “Prior to commerce media and LLM powered Agentic Commerce, brands were often flying blind with little visibility into or engagement with the actual purchase. DaVinci Commerce makes it easy for brands to engage consumers and connect the dots between exposure, discovery and purchase, delivering powerful insights to brands and personalized experiences to consumers.”

DaVinci Commerce enables brands to operationalize agentic AI across commerce marketing through two core capabilities:

• Commerce Content Optimization: Use AI to generate, optimize, and deliver ads and content for programmatic media, enabling personalization without sacrificing scale.
• Commerce Media Activation: Launch AI-powered commerce media campaigns in under five minutes, dramatically reducing time-to-market while preserving brand, legal, and retailer guardrails.

Originally launched in August 2023, DaVinci Commerce now supports agentic shopping experiences that connect consumers directly with AI-driven shopping agents. Rather than sending users to crowded product landing pages, the platform generates personalized prompts and guided shopping conversations and discovery that help consumers evaluate options and complete purchases in real time—linking ad exposure to verified transaction data and incremental sales measurement.

The rebrand to DaVinci Commerce reflects the company’s commitment to leading the next era of commerce marketing—one where AI agents work alongside humans to accelerate execution without sacrificing trust or control.

About DaVinci Commerce
DaVinci Commerce is an Agentic Commerce Marketing platform built for the next era of AI-powered commerce. Formerly Jivox, the company enables global brands and commerce media networks to use agentic AI to scale customer engagement and acquisition across digital and in-store commerce environments.

DaVinci Commerce brings together generative AI, agentic workflows, and enterprise guardrails to help enterprise customers move from creative to activation in minutes, not weeks. Its platform supports commerce content optimization, rapid commerce media activation, and agentic shopping experiences that connect marketing exposure to measurable sales outcomes.

Trusted by Nestlé, Diageo, Giant Eagle, Nordstrom, and many more, DaVinci Commerce delivers speed, scale, and precise personalization to make digital commerce a sales growth engine.

For more information, visit www.davincicommerce.ai.

SOURCE DaVinci Commerce

Cytotheryx’s Series A financing, alongside strategic debt funding, will advance its cell therapy programs toward clinical development and support GMP manufacturing scale-up.

ROCHESTER, Minn., Jan. 12, 2026 — Cytotheryx, Inc. , a preclinical cell therapy company developing cell-based treatments for liver disease, today announced a lead term sheet from Ouroboros Family Founders Fund I, LP for its $60 million Series A financing, positioning the Company to advance multiple programs into the clinic. In parallel, Cytotheryx secured additional debt financing from QRS Investments, LLC to expand its real estate footprint, enable GMP manufacturing capacity and support continued operational scale-up.

These financings highlight the durability and increasing relevance of next-generation cell therapy platforms despite a challenging biotech investment environment. Cytotheryx’s differentiated platform addresses a substantial unmet need in acute, chronic, and rare liver diseases by delivering a scalable supply of clinically relevant, fully functional human hepatocytes, or liver cells, and leveraging those cells across multiple therapeutic applications.

“Securing a lead Series A term sheet alongside complementary debt financing represents a pivotal milestone for Cytotheryx,” said Dr. John Swart, Chief Executive Officer. “This financing positions us to accelerate multiple programs into the clinic and underscores strong investor confidence in our cell therapy platform and its potential to meaningfully advance the treatment paradigm for liver disease.”

Cytotheryx’s technology portfolio spans a proprietary bio-incubator platform for scalable liver cell production, a bioartificial liver support system for the treatment of acute liver failure, and a universal liver cell therapy designed for transplantation in patients with rare genetic and chronic liver diseases. Together, these technologies position Cytotheryx as a leader in liver cell therapy innovation and underscore its potential to deliver transformative therapies to patients worldwide.

To learn more, the Company will present at the Biotech Showcase during JPM Week in San Francisco on Monday, January 12, at 2:30 p.m. PST. 

Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding Cytotheryx’s financing, development plans, and anticipated advancement of its cell therapy programs. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. No undue reliance should be placed on these forward-looking statements, which speak only as of the date of this release.

About Cytotheryx
Cytotheryx, Inc. is a preclinical cell therapy company leveraging proprietary technology to address acute, chronic, and rare genetic liver diseases. A Mayo Clinic spinout, Cytotheryx has developed a differentiated platform that enables the scalable production of clinically relevant, fully functional primary human hepatocytes for therapeutic use.

SOURCE Cytotheryx, Inc.